Currently, a phase I trial is underway for oligonucleotide therapy targeting the long non-coding RNA TUG1 in recurrent glioblastoma, which provides a direct reference for targeting LINC02167 in therapy [60]. The gene discussed is TUG1; the disease is glioblastoma.